protocol unlikely, e.g. drug abuse, alcoholism, psychiatric instability, inadequate 
motivation. 
5. Participation in another investigational therapeutic study within the previous 90 days. 
III.B. Patient Evaluation 
The following evaluations will be performed at various times throughout the study: 
1 . History and physical examination 
A history relevant to the manifestations of both cystic fibrosis and unrelated diseases 
will be taken. A full review of systems, medication usage, and drug allergy history will 
be obtained. 
2. Clinical laboratory evaluations: 
a) Blood: Hemoglobin, hematocrit, white blood cell count, white blood cell 
differential count, platelet count, Westergren sedimentation rate. Serum 
electrolytes (sodium, potassium, chloride, bicarbonate) BUN, creatinine, 
glucose, uric acid, total protein, albumin, calcium, phosphate, total bilirubin, 
conjugated bilirubin, AST, ALT, alkaline phosphatase, LDH. 
b) Urine analysis: Qualitative protein, blood, glucose, ketones, pH. Microscopic 
examination. 
3. Pulmonary function tests 
Testing will be performed in the University of Michigan Pulmonary Function Laboratory 
and will meet the standards set by the American Thoracic Society [1987a, 1987b] 
a) Spirometry using the normal predicted values of Crapo et al. [1981]. 
b) Absolute lung volumes (total lung capacity, thoracic gas volume, residual 
volume) 
c) Diffusion capacity, single breath 
4. Arterial blood gases and pulse oximetry while breathing room air 
5. Electrocardiogram (12-lead) 
6. Postero-anterior and lateral chest x-ray 
7. Thin-cut computerized tomography of the chest 
8. Aerobic bacterial culture of sputum with antibiotic sensitivities 
9. Shwachman-Kulczycki score calculation 
Recombinant DNA Research, Volume 16 
[821] 
